Bjørn Christer Linder Grønvold

• Vo, Camilla Dao; Myhre, Anders Eivind; Abrahamsen, Ingerid Weum; Remberger, Mats; Mattsson, Jonas & Fløisand, Yngvar [Vis alle 10 forfattere av denne artikkelen] (2023). Allogen stamcelletransplantasjon hos voksne 2015–21. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(4). doi: 10.4045/tidsskr.22.0521. Fulltekst i vitenarkiv
• Ali, Maryan Mohamed; Grønvold, Bjørn Christer Linder; Remberger, Mats; Abrahamsen, Ingerid Weum; Myhre, Anders Eivind & Tjønnfjord, Geir Erland [Vis alle 8 forfattere av denne artikkelen] (2021). Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival. Clinical Lymphoma, Myeloma & Leukemia. ISSN 2152-2650. 21(9), s. 598–605. doi: 10.1016/j.clml.2021.05.003. Fulltekst i vitenarkiv

Se alle arbeider i Cristin

• Grønvold, Bjørn Christer Linder; Ali, M.M.; Remberger, M.; Mattsson, J.; Egeland, Torstein & Lundin, Katrin [Vis alle 13 forfattere av denne artikkelen] (2020). HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplantation. ISSN 0268-3369. 55(8), s. 1658–1661. doi: 10.1038/s41409-020-0827-3.
• Abrahamsen, Ingerid Weum; Grønvold, Bjørn Christer; Inderberg, Else Marit ; Mensali, Nadia; Mattsson, Jonas & Gedde-Dahl, Tobias (2020). Posttransplantation Lymphoproliferative Disease Treated by Retransplantation. Case Reports in Immunology. ISSN 2090-6609. 2020. doi: 10.1155/2020/9403123. Fulltekst i vitenarkiv Vis sammendrag

  Epstein–Barr virus- (EBV-) induced posttransplantation lymphoproliferative disease (PTLD) is a life-threatening complication following allogeneic stem cell transplantation. *e main risk factor is anti-thymocyte globulin (ATG). Patients who fail first-line treatment with rituximab have a poor prognosis. *ough adoptive transfer of EBV-specific T cells is a potentially effective option, it is not readily available. In this case report, the patient developed PTLD following transplantation for aplastic anemia using ATG as part of the conditioning. He failed rituximab treatment and developed graft failure. We were aware that the stem cell donor had a recent EBV infection prior to transplantation, whereas the patient most likely was EBV negative before transplant. We describe our strategy to meet the patient’s urgent need for EBV-specific Tcells, as well as new hematopoietic stem cells. *e same donor was used for a second transplant, using peripheral blood stem cells. *e conditioning used was thiotepa/busulfan/fludarabin with a single dose of cyclophosphamide after transplant as graft-versus-host disease (GVHD) prophylaxis. *e EBV DNA levels fell when conditioning was started, and have been undetectable since day +15 and remained so till 18 months after transplantation. *e patient is doing well. *is case reports successful use of cyclophosphamide after transplantation as GVHD prophylaxis, preserving virus-specific immunity.

Se alle arbeider i Cristin